Preferred Label : Allogeneic Anti-CD38 DAR-T Cells STI-1492;
NCIt synonyms : Allogeneic Anti-CD38 A2 KOKI DAR T-cells STI-1492; Anti-CD38 A2 KOKI DAR Allogeneic T Cells STI-1492; Allogeneic Anti-CD38 Dimeric Antigen Receptor-expressing T-lymphocytes STI-1492; Allogeneic Second Generation Anti-CD38 Knock-out Knock-in Dimeric Antigen Receptor-4-1BB-CD3zeta-expressing
T-cells STI-1492;
NCIt definition : A preparation of human allogeneic T-lymphocytes that are gene-edited with the clustered
regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to
disrupt the expression of endogenous T-cell receptor (TCR) alpha and to express a
dimeric antigen receptor (DAR) composed of a fragment antigen-binding variable region
(Fab) recognizing the tumor-associated antigen (TAA) cluster of differentiation 38
(CD38), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta
chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating
and antineoplastic activities. Upon intravenous administration, allogeneic anti-CD38
DAR-T cells STI-1492 are directed to and induce selective toxicity in CD38-expressing
tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune
cells and hematologic malignancies, and its expression has been correlated with poor
prognosis. The disruption of endogenous TCR alpha prevents graft-versus-host disease
(GvHD).;
Molecule name : STI 1492; STI-1492;
NCI Metathesaurus CUI : CL1770942;
Origin ID : C182613;
UMLS CUI : C5666888;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
